| Literature DB >> 21486188 |
Julie Laloy1, Séverine Robert, Catherine Marbehant, François Mullier, Jorge Mejia, Jean-Pascal Piret, Stéphane Lucas, Bernard Chatelain, Jean-Michel Dogné, Olivier Toussaint, Bernard Masereel, Stéphanie Rolin.
Abstract
We validated a preclinical toxicological screening assay and provided guidelines to evaluate the potential impact of nanoparticles (NPs) on blood coagulation. Five NPs with various physicochemical properties were studied using several existing methods of clotting times and thrombin generation assays in human normal pool plasma. In both recalcification clotting time (RCT) and calibrated thrombin generation test (cTGT), the NPs exhibited procoagulant activity (SiO₂ ≥ SiC ≥ TiC > CuO > CB) but cTGT was more sensitive and relevant than RCT. Thus, the cTGT appears as a reference assay to investigate the nanoparticle (NP) procoagulant activity in human plasma. It should be used as the reference toxicity test for evaluating the effects of nanomaterials on coagulation cascade. In addition, we also showed that the use of the Pluronic F-108 dispersant and/or the sonication for the NP suspension preparation may mask their procoagulant activity and thus should be avoided.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21486188 DOI: 10.3109/17435390.2011.569096
Source DB: PubMed Journal: Nanotoxicology ISSN: 1743-5390 Impact factor: 5.913